**Core tip:** We investigated the use of droplet digital polymerase chain reaction (ddPCR) for detecting host mRNA markers in stools as a non-invasive test for colorectal cancer screening using *ITGA6* and *ITGA6A* as established medium and low abundance stool biomarkers. Our side by side comparison of ddPCR and qPCR on stool samples obtained from patients with advanced adenomas and colorectal cancers and controls using duplex TaqMan reactions revealed that both methods performed equally well.

INTRODUCTION
============

Colorectal cancer (CRC) is one of the most common causes of cancer-related mortality worldwide, now accounting for more than 600000 deaths annually just in the United States\[[@B1]\]. Early detection is a key factor in reducing mortality from CRC\[[@B2]-[@B4]\]. The extent of the spread of the disease in terms of local invasion as well as to lymph nodes and distal organs at the time of diagnosis is an important prognostic factor, with five year survival rates of more than 90% for localized CRC but only about 10% for CRC having metastasized to distant organs\[[@B5]\]. Several screening regiments for CRC are recommended such as fecal occult blood testing and colonoscopy. While colonoscopy remains the gold standard for the detection of colorectal lesions (up to 95% sensitivity for cancer and 76% for adenomas), compliance is low owing to discomfort and unpleasant preparation procedures\[[@B6]\]. The risk of complications, cost and access are other limitations of this procedure. On the other hand, the improved immunological version of fecal occult blood testing, which detects human hemoglobin, has been used for some time but poor precursor lesion detection rates (66%-80% sensitivity for cancer but only 10%-28% for adenomas) albeit an excellent specificity (95%) limit its utility\[[@B3],[@B7]-[@B9]\]. It is therefore imperative to explore alternate or complementary strategies with the potential to improve CRC screening performance, especially for the detection of cancers at their early stages.

Non-invasive stool testing represents an advantageous as well as a biologically rational approach based on the high rate of tumor cell exfoliation into the lumen for neoplasm detection through DNA- and RNA-based approaches\[[@B10]-[@B15]\]. Detection of host mRNA in stools has been reported to be particularly challenging considering that human mRNA is expected to represent less than 1% of total stool RNA\[[@B16]\] and that stool mRNA may be particularly sensitive to degradation\[[@B3],[@B17]\]. Nevertheless, the potential usefulness of detecting specific transcripts in feces for CRC screening was demonstrated more than two decades ago, using first generation PCR\[[@B18],[@B19]\]. More recently, using TaqMan quantitative PCR (qPCR), a number of transcripts such as *PTGS2* (COX-2), *B2M*, *CEACAM5*, *CDH1*, *ITGA6*, *MYC* and *GADD45B* are now listed among the stool mRNA known to be up-regulated in patients with CRC\[[@B10],[@B20]\]. Interestingly, a few other genes such as *PTPRC* (CD45) and *ITGA6A* have been detected at low levels, but only in patients with CRC\[[@B10],[@B20]\], making them of particular interest for their specificity. One may now wonder if a more sensitive assay for mRNA detection could improve the reliability of these specific biomarkers in a non-invasive test for CRC detection.

In the present study, we addressed this question in the context of the development of droplet digital PCR (ddPCR), a now commercially available technology identified as third generation PCR, claimed to be of an unprecedented sensitivity\[[@B21],[@B22]\]. Besides the obvious interest in the detection of rare mutations of various kinds, ddPCR technology displays a number of additional advantages for general nucleic acid quantification\[[@B23],[@B24]\] such as the capability to obtain absolute quantification without the need of standard dilution curves and reaction efficiency determination\[[@B22],[@B23]\]. Another potential advantage of ddPCR technology, being an end-point approach, is the reaction tolerance to PCR inhibitors\[[@B22]\], an important advantage when using clinical samples\[[@B25]\].

The integrin α6 subunit has been extensively characterized in CRC cell lines and primary tumors as being up-regulated\[[@B26],[@B27]\] together with its β4 partner\[[@B28]\] to form a pro-proliferative α6β4 laminin receptor\[[@B27],[@B29]\]. In this proof-of-concept comparative study, we used *ITGA6* (integrin α6 subunit) and *ITGA6A* (its α6A variant) as representative medium and low detectable stool target genes, respectively, as demonstrated previously\[[@B20]\]. Our results show that when analyzed side by side using duplex TaqMan reactions, qPCR and ddPCR methods performed with comparable sensitivity for the detection of these two target genes in stools of patients with colorectal lesions.

MATERIALS AND METHODS
=====================

Patients and samples
--------------------

Detailed information pertaining to the samples used in this work has been provided in a previous study\[[@B20]\]. Briefly, the study cohort used herein included 24 patients with advanced adenomas (Ad; defined as being larger than 1 cm at the greatest dimension) as well as 65 patients with stage II-IV CRC (32 stage II; 22 stage III and 11 stage IV) that were diagnosed by colonoscopy and histology. A total of 30 patients with no pathological findings were used as controls. For control patients and patients with adenomas, stools samples were collected before colonoscopy while patients with CRC provided samples 2-4 wk after colonoscopy and biopsy (but before surgery)\[[@B18]\].

RNA isolation, reverse transcription and preamplification
---------------------------------------------------------

Isolation of RNA from fecal specimens was performed according to a procedure described previously\[[@B10],[@B18]\]. cDNA was synthesized using M-MLV Reverse Transcriptase, RNase H Minus (Takara Bio Inc., Otsu, Japan) with 0.375 μg total RNA from stools and 750 ng random hexamers in a final reaction volume of 60 μL. For preamplification, the TaqMan PreAmp Master Mix Kit (Life Technologies) was used to provide unbiased, multiplex preamplification of specific amplicons for analysis with TaqMan gene expression assays. Commercially available TaqMan primer and probe mixtures were used for the amplification of ITGA6 (Hs01041011_m1 labelled with the reporter dye VIC) and ITGA6A (Hs01041013_m1 labelled with the reporter dye FAM). Briefly, 20 × TaqMan gene expression assays were pooled at a final concentration of 0.2 × in 1 × TE, combined with 5 μL fecal cDNA and 2 × TaqMan PreAmp Master Mix in a total volume of 20 μL, then preamplified for 14 PCR cycles of 15 s at 95 °C and 4 min at 60 °C. Linear amplification of the cDNA samples using the preamplification kit under these conditions has been previously verified\[[@B20]\]. Preamplification products were diluted 1:20 with 1 × TE buffer, aliquoted and stored at -80 °C.

qPCR
----

Duplex qPCR reactions were prepared by combining 1 μL of the 20 × diluted preamplification products with 10 μL TaqMan Gene Expression Master Mix and 1 μL of each 20 × TaqMan Gene Expression Assay in a total volume of 20 μL. qPCR was performed for 60 cycles of 30 s 95 °C, 1 min 60 °C in an Mx3000P Real Time PCR machine (Stratagene, Mississauga, Ontario) and read in both the FAM and HEX channels.

ddPCR
-----

Twenty microliters of each reaction mix containing 10 μL ddPCR Supermix for Probes (BioRad), 1 μL of each 20 × TaqMan Gene Expression Assay for ITGA6A and ITGA6 and 1 μL of each 20 × diluted preamplification product was converted to droplets using the QX200 droplet generator (BioRad). Droplet-partitioned samples were then transferred to a 96-well plate, sealed and cycled in a MyCycler Thermocycler (BioRad). DNA polymerase activation was at 94 °C for 10 min, followed by 45 cycles of 94 °C for 30 s and 55 °C for 1 min and a post-cycling step of 98 °C for 10 min for enzyme inactivation. The cycled plate was then transferred and read in the FAM and HEX channels using the QX200 reader (BioRad).

Data presentation and statistical analysis
------------------------------------------

Stool mRNA detection results were presented as copy number per microlitre for both PCR assays. For each gene, a standard reference curve was generated for *ITGA6* and *ITGA6A* using serial 2 fold dilutions of a cDNA stock solution of the target sequence quantified using a NanoDrop 1000 spectrophotometer (NanoDrop, Wilmington, DE, United States).

For statistics, data were analyzed as previously described\[[@B20]\] using Prism 6 software (GraphPad). Correlations of stool mRNA detection by qPCR and ddPCR were evaluated using the nonparametric Spearman correlation test. Comparisons of mRNA expression in stool samples from controls and patients with lesions were expressed as median with interquartile range and analyzed by the Kruskal-Wallis test followed by Dunn's multiple comparison tests. Areas under the receiver operating characteristic (ROC) curves were calculated using Prism 6. Sensitivities and specificities were expressed in % with a 95% confidence interval (CI). Optimal cutoff values were calculated with Cutoff Finder\[[@B30]\]. Statistical significance was defined as *P* \< 0.05.

RESULTS
=======

The mRNA levels of *ITGA6* and *ITGA6A* were evaluated in the same sets of stool samples obtained from patients diagnosed with Ad or CRC and controls in duplex for both PCR methods. For each group, results were expressed as median transcript copy number.

By ddPCR, the median levels of *ITGA6* transcript detection in stools of patients with colorectal lesions were found to be statistically significantly increased as compared to those of the controls (Figure [1A](#F1){ref-type="fig"}). As compared to controls, the *ITGA6* mRNA levels were approximately 8 times higher for Ad (*P* \< 0.0001) and 6-11 times for CRC, depending on the stage (*P* \< 0.002-0.0001; 11 times when stages II + III are considered, *P* \< 0.0001). ROC analysis of *ITGA6* showed an area under the curve (AUC) of 0.89 (*P* \< 0.0001) for the prediction of stages II and III CRC with 78% sensitivity and 93% specificity and of 0.91 (*P* \< 0.0001) for the prediction of Ad with 96% sensitivity and 69% specificity (Figure [1B](#F1){ref-type="fig"}). The detection of *ITGA6A*, a pro-proliferative *ITGA6* splicing variant up-regulated in CRC cells\[[@B26],[@B27]\], was also investigated in the stools of patients with colorectal lesions. *ITGA6A* levels detected in the stools of control patients were very low while found to be significantly more elevated (over 40 times) in the stools of patients with stages II and III CRC (*P* \< 0.0002). Analyses of the *ITGA6A*/*ITGA6* ratios revealed that *ITGA6A* represented less than 1% and 3% of the total *ITGA6* copy number in the stools of control or Ad patients, respectively, but approximately 10% in the stools of patients with stage II or III CRC (Figure [1D](#F1){ref-type="fig"}).

![Detection of *ITGA6* and *ITGA6A* in stool samples of controls and patients diagnosed with Ad and stage II-IV CRC by duplex ddPCR. A: For total *ITGA6*, significant increases in copy number were observed for Ad and all tested CRC stages relative to the controls (Ctrl); B: ROC curve analysis of *ITGA6* detection in Ad and in stages II-III CRC. Area under the curve (AUC), sensitivity and specificity are provided (95%CI); C: For *ITGA6A*, significant increases in copy number were only observed for stage II and stage III CRC relative to Ctrl; D: Accordingly, *ITGA6A*/*ITGA6* ratios were found to be significantly different between controls and stage II and III CRC. Results in A, C and D are expressed as median (interquartile range) of copy number relative to control patients. ^a^*P* \< 0.05, ^c^*P* \< 0.01, ^e^*P* \< 0.001 using the Kruskal-Wallis test followed by Dunn's multiple comparison test.](WJG-23-2891-g001){#F1}

Overall, the results using duplex ddPCR for *ITGA6* and *ITGA6A* were found to be comparable to those reported previously with conventional qPCR\[[@B20]\] albeit with an apparent underestimation of the general *ITGA6A*/*ITGA6* ratio. To ensure a valid comparison of the PCR methods, the same samples as above were run in parallel in duplex qPCR. As shown in Figure [2](#F2){ref-type="fig"}, the results were very similar to those obtained with ddPCR. For instance, ROC analysis of *ITGA6* showed comparable AUC of 0.90 (*P* \< 0.0001) and 0.91 (*P* \< 0.0001) for the prediction of stage II + III and Ad, respectively (Figure [2B](#F2){ref-type="fig"}). In fact the only notable distinction in the data obtained using qPCR was the more elevated *ITGA6A/ITGA6* ratios resulting in an estimation of the proportion of ITGA6A at 2% and 9% of the total ITGA6 for control and Ad patients and up to 25% in the stools of patients with stage II and III CRC. This appears consistent with the apparent slight under-estimation of ITGA6 and over-estimation of ITGA6A. To verify this phenomenon, the linearity between the two sets of samples generated with ddPCR and qPCR was evaluated using nonparametric Spearman analysis. As shown in Figure [3](#F3){ref-type="fig"}, a significant correlation was obtained for both ITGA6 (*r* = 0.9754) and ITGA6A (*r* = 0.9334) confirming that the inter-variations between the ddPCR and qPCR analyses were uniform and not the result of a subset of divergent samples.

![Detection of *ITGA6* and *ITGA6A* in stool samples of controls and patients diagnosed with Ad and stage II-IV CRC by duplex qPCR. A: For total *ITGA6*, significant increases in copy number were observed for Ad and all tested CRC stages relative to Ctrl; B: ROC curve analysis of *ITGA6* detection in Ad and in stages II-III CRC. AUC, sensitivity and specificity are provided (95%CI); C: For *ITGA6A*, significant increases in copy number were only observed for stage II and stage III CRC relative to Ctrl; D: Accordingly, *ITGA6A*/*ITGA6* ratios were found to be significantly different between controls and stage II and III CRC. Results in A, C and D are expressed as median (interquartile range) of copy number relative to control patients. ^a^*P* \< 0.05, ^c^*P* \< 0.01, ^e^*P* \< 0.001 using the Kruskal-Wallis test followed by Dunn's multiple comparison test.](WJG-23-2891-g002){#F2}

![Correlation between ddPCR and qPCR measurements. *ITGA6* (A) and *ITGA6A* (B) levels (copy number) detected in controls (Ctrl: white), Ad (red) and CRC (blue) were plotted and evaluated using the nonparametric Spearman correlation test.](WJG-23-2891-g003){#F3}

DISCUSSION
==========

In the present study, we have compared side by side ddPCR and qPCR for the detection of *ITGA6* and *ITGA6A* transcripts in stool samples obtained from patients with various types of colorectal lesions and controls and have shown that both methods performed with comparable sensitivity for the two target genes. While expected for *ITGA6*, which is a relatively abundant transcript ubiquitously expressed in normal and cancer intestinal epithelial cells\[[@B26],[@B31]\], the comparable sensitivity in the detection of its *ITGA6A* variant was more surprising considering that it is less abundant, its expression being restricted to the lower crypt cells which do not extrude into the lumen\[[@B31]\] and to colorectal cancer cells\[[@B26]\]. Indeed, ddPCR has been shown to be more sensitive to detect low expression targets and to be more tolerant to PCR inhibitors\[[@B21]-[@B24]\], two advantages that could have increased stool ITGA6A detection. For instance, ddPCR was recently successfully used for the measurement of inflammatory transcripts in stools of children confirming that this method can be used in clinical investigation\[[@B16]\].

Recent studies compared quantitative to digital PCR for the detection of pathogens in clinical stool samples. The ddPCR assay was reported to perform better than qPCR for the detection of human cytomegalovirus, mainly because it was less susceptible to PCR inhibitors\[[@B25]\]. In another study designed for the enumeration of *Cryptosporidium* oocysts, ddPCR was also reported to be less affected by the presence of inhibitors but overall, once qPCR data were corrected for pipetting and DNA losses, the sensitivity of both methods was considered to be comparable\[[@B32]\]. In a third study, digital PCR outperformed SYBR green-based qPCR for the detection of fecal enterotoxigenic *Bacteroides fragilis* but provided similar results compared to TaqMan qPCR\[[@B33]\]. It is noteworthy that we also used *TaqMan* Gene Expression Assays for *ITGA6* and *ITGA6A* in order to allow direct comparison between duplex ddPCR and qPCR.

Use of TaqMan assays has been favored for the detection of host mRNA in stools for better sensitivity\[[@B10],[@B20]\] and also because they are not susceptible to the generation of primer-dimers, a phenomenon frequently observed for low expression targets in complex biological samples by the SYBR green method\[[@B34]\]. TaqMan qPCR may also be less affected by PCR inhibitors than SYBR green-based qPCR\[[@B33]\]. In this context, it is noteworthy that the specificities for *ITGA6A* detection in patients with CRC vs control patients were over 96% for both PCR methods (ddPCR: 96.6 %; qPCR: 96.7%). With such low levels of false positives combined with a sensitivity of 65% for both methods, *ITGA6A* appears to be an excellent candidate biomarker for inclusion in a multiplex stool RNA assay for CRC screening. It is interesting to note that the failure of *ITGA6A* to detect patients with Ad is consistent with our previous observation that *ITGA6A* is only significantly overexpressed in CRC lesions\[[@B26],[@B27]\]. On the other hand, the areas under the ROC curves for *ITGA6* determined by ddPCR and qPCR were 0.91 for Ad and 0.89 and 0.90, respectively, for CRC, confirming our previous findings on the usefulness of *ITGA6* in the detection of colorectal lesions in a non-invasive assay.

Taken together, these data indicate that both TaqMan qPCR and ddPCR perform well in this duplex assay comprised of the moderately abundant target transcript *ITGA6* and its scarcer variant *ITGA6A*. One of the main advantages of ddPCR is that it provides absolute quantification of the target DNA in copy number to a point where it has been proposed for the construction of calibration curves\[[@B22],[@B23],[@B35]\]. Direct comparison of the results obtained with the two techniques revealed strong correlations between ddPCR and qPCR measurements. Interestingly, the yields observed for ddPCR were slightly higher for *ITGA6* but lower for *ITGA6A* than for qPCR resulting in an apparent 2-3-fold overestimation of *ITGA6A* relative to the total *ITGA6* by qPCR in the stools of patients with CRC. These differences in target quantitation between ddPCR and qPCR are comparable to those reported by other authors\[[@B22],[@B36]\].

In conclusion, we found that *ITGA6* and *ITGA6A* detection with ddPCR was comparable to that of qPCR using TaqMan assays. Considering the cost of ddPCR is estimated to be five times that of TaqMan qPCR\[[@B33]\] while qPCR allows the processing of more samples per run, we agree with the suggestion that ddPCR is optimal for calibrating targets for subsequent use on other platforms such as qPCR\[[@B22],[@B23],[@B35]\].
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Background
----------

Because colorectal cancer can be successfully treated before the occurrence of metastasis, early and efficient diagnosis of the colorectal lesions is important. Currently approved non-invasive methods based on the detection of biomarkers in the stool include fecal occult blood and more recently, stool host DNA. Unfortunately, the sensitivity of these methods for detecting precancerous lesions remains low. Detection of host mRNA in stools has been also investigated over the last 2 decades and lead to the identification of a number of transcripts up-regulated in patients with colorectal cancers.

Research frontiers
------------------

Detection of host mRNA in stools appears challenging considering its low proportion in regard to total stool RNA and its particular sensitivity to degradation. Efficient mRNA detection protocols are thus needed to insure the reliability of this approach.

Innovations and breakthroughs
-----------------------------

In this proof of concept study, we compared side by side droplet digital polymerase chain reaction (PCR) to quantitative PCR using duplex TaqMan reactions for the detection of the two previously characterized stool colorectal cancer markers ITGA6 and ITGA6A. These results show that the two methods performed well, showing comparable sensitivity for the detection of the two targets genes in the stools of patient with colorectal lesions.

Applications
------------

These findings suggest that although droplet digital PCR has some advantages, its sensitivity for detection seems comparable to the less expensive quantitative PCR when using duplex TaqMan reactions.

Terminology
-----------

Droplet digital PCR is a now commercially available technology for DNA amplification considered as third generation PCR, relative to its previous generation, the quantitative PCR. TaqMan assays consist of the use of a pair of unlabeled primers with a specific labeled probe, which increase specificity of PCR.

Peer-review
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This is an interesting and well written study on droplet digital PCR for quantification of *ITGA6* in a stool mRNA assay for the early detection of colorectal neoplasms.
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